|
|
Volumn 12, Issue 7, 2001, Pages 883-
|
|
Chemotherapy in cervical cancer: Is cisplatin alone still the standard of care?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BLEOMYCIN;
CISPLATIN;
IFOSFAMIDE;
MITOLACTOL;
MITOMYCIN C;
VINDESINE;
CANCER ADJUVANT THERAPY;
CANCER CHEMOTHERAPY;
CANCER CONTROL;
CANCER GROWTH;
CANCER LOCALIZATION;
CANCER RADIOTHERAPY;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
EDITORIAL;
FEMALE;
HEALTH CARE POLICY;
HUMAN;
PATIENT CARE;
PREVALENCE;
PRIORITY JOURNAL;
PROSPECTIVE STUDY;
RANDOMIZED CONTROLLED TRIAL;
SIDE EFFECT;
STANDARD;
TREATMENT OUTCOME;
UTERINE CERVIX CANCER;
UTERUS SURGERY;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CISPLATIN;
DRUG ADMINISTRATION SCHEDULE;
FEMALE;
HUMANS;
PRACTICE GUIDELINES;
UTERINE CERVICAL NEOPLASMS;
|
|
EID: 0034898549
PISSN: 09237534
EISSN: None
Source Type: Journal
DOI: 10.1023/A:1011188330076 Document Type: Editorial |
|
Times cited : (2)
|
|
References (2)
|
